Specialty· August 14, 2026 · 24 min read
Topic
Multiple Myeloma
Multiple myeloma drug access, BCMA CAR-T therapies, bispecific antibodies, and relapsed/refractory regimens.
Approvals· August 7, 2026 · 14 min read
Iberdomide FDA PDUFA review: first-in-class CELMoD for multiple myeloma
By Ran Chen#FDA Approval#Multiple Myeloma#Oncology
Deals· August 6, 2026 · 13 min read
Gilead's $7.8B Arcellx Acquisition: Anito-Cel Deal Anatomy
By Ran Chen#Gilead Sciences#Arcellx#anito-cel